{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-294108","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2025-11-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.456417+00:00","generated_at":"2026-05-16T17:12:45.009582+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Aptose Biosciences to be acquired by Hanmi Pharmaceutical for C$2.41 per share in cash","bullets":["Hanmi subsidiary will acquire all outstanding Aptose shares at C$2.41 each, a 28% premium over the 30-day VWAP of C$1.88 on TSX.","Aptose board unanimously recommends the arrangement after unanimous recommendation from a special committee of independent directors.","Transaction requires approval by two-thirds of votes cast and minority approval excluding Hanmi affiliates; special meeting by Jan 16, 2026.","Non-solicitation provisions with a C$300,000 expense fee payable to Hanmi if agreement terminated under certain conditions.","Post-closing, Aptose shares will be delisted from TSX and the company will cease reporting under Canadian securities legislation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-294108","json":"https://secwatch.observer/filing/0001193125-25-294108.json","markdown":"https://secwatch.observer/filing/0001193125-25-294108.md","text":"https://secwatch.observer/filing/0001193125-25-294108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000119312525294108/0001193125-25-294108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000119312525294108/d25723d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-16T17:12:45.009582+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c220708b5480e702569e92164ea47d9c8ddc5164","claim":"Aptose Biosciences Inc. entered into Arrangement Agreement with Hanmi Pharmaceuticals Co. Ltd. and HS North America Ltd. valued at C$2.41 in cash per Common Share (effective 2025-11-18).","evidence_excerpt":"On November 18, 2025, Aptose Biosciences Inc. (the “ Company ”), Hanmi Pharmaceuticals Co. Ltd. (“ Hanmi ”) and HS North America Ltd., a wholly owned subsidiary of Hanmi (“ Hanmi Purchaser ” and together with Hanmi, the “ Hanmi Purchasers ”), entered into a definitive arrangement agreement (the “ Arrangement Agreement ”) pursuant to which Hanmi Purchaser will acquire all of the issued and outstanding common shares of the Company","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000119312525294108/0001193125-25-294108-index.htm","confidence":0.98,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Hanmi Pharmaceuticals Co. Ltd. and HS North America Ltd."},{"label":"Value","value":"C$2.41 in cash per Common Share"},{"label":"Effective","value":"2025-11-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}